Treatment discontinuation effects on bone turnover and BMD with risedronate

被引：0
|
作者：
Watts, N
Olszynski, WP
McKeever, CD
Grauer, A
Chines, A
机构：
[1] Univ Cincinnati, Cincinnati, OH 45221 USA
[2] Midtown Med Ctr, Saskatoon, SK, Canada
[3] McKeever Orthoped Clin, Houston, TX USA
[4] Procter & Gamble Pharmaceut, Mason, OH USA
来源：
BONE | 2004年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S99 / S99
页数：1
相关论文
共 50 条
  • [21] Bone turnover marker reductions after 24 months of treatment with risedronate: results from the risedronate male osteoporosis study
    Boonen, S.
    Garnero, P.
    Guo, C-Y.
    Eusebio, R.
    Delmas, P. D.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S24 - S24
  • [22] Strontium ranelate: changes in BMD and bone markers one year after treatment discontinuation
    Ortolani, S.
    Diaz-Curiel, M.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S25 - S25
  • [23] How useful are measures of BMD and bone turnover?
    Miller, PD
    Hochberg, MC
    Wehren, LE
    Ross, PD
    Wasnich, RD
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (04) : 545 - 553
  • [24] Bone turnover marker reductions after 24 months of treatment with risedronate: Results from the risedronate male osteoporosis study
    Boonen, S.
    Garnero, P.
    Guo, C. Y.
    Eusebio, R.
    Delmas, P. D.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S119 - S119
  • [25] RELATIONSHIP BETWEEN SUPPRESSION OF BONE TURNOVER MARKERS AND FUTURE INCREASES IN BONE MINERAL DENSITY IN RISEDRONATE TREATMENT
    Mawatari, T. M.
    Muraoka, M.
    Iwamoto, Y. I.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S354 - S355
  • [26] Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months
    Bolland, Mark J.
    Grey, Andrew B.
    Horne, Anne M.
    Briggs, Simon E.
    Thomas, Mark G.
    Ellis-Pegler, Rod B.
    Callon, Karen E.
    Gamble, Greg D.
    Reid, Ian R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 (08) : 1304 - 1308
  • [27] Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis
    Atmaca, Aysegul
    Gedlik, Olcay
    ADVANCES IN THERAPY, 2006, 23 (06) : 842 - 853
  • [28] Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis
    Aysegul Atmaca
    Olcay Gedik
    Advances in Therapy, 2006, 23 : 842 - 853
  • [29] Comparison of BMD Changes and Bone Turnover Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON Studies.
    Kim, Tiffany
    Bauer, Douglas
    Schafer, Anne
    Cosman, Felicia
    Black, Dennis
    Eastell, Richard
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S26 - S26
  • [30] EFFECTS OF GLUCOCORTICOIDS TREATMENT ON BONE BMD AND TBS IN MEN
    Winzenrieth, R.
    Leib, E.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 : S685 - S685
12345